Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (6): 54-64.doi: 10.6040/j.issn.1671-7554.0.2024.0074

• Clinical Medicine • Previous Articles    

Prediction of lateral lymph node metastasis in papillary thyroid carcinoma larger than 10 mm

LIN Yuyang, WANG Bei, LI Fei   

  1. Department of Medical Ultrasound, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, Shandong, China
  • Published:2024-07-15

Abstract: Objective To predict the occurrence of lateral lymph node metastasis(LLNM)in papillary thyroid carcinoma(PTC)larger than 10 mm in diameter(non-T1A stage)and analyze the metastatic pattern. Methods A retrospective analysis was conducted on 166 PTC patients with the foci diameters larger than 10 mm who underwent thyroidectomy combined with lateral lymph node dissection. Clinicopathological characteristics were evaluated, and the occurrence and pattern of LLNM were analyzed. Univariate and multivariate Logistic regression analyses were used to assess the factors associated with LLNM. A nomogram model was established based on the results, and the receiver operating characteristic(ROC)curve was utilized to evaluate the models accuracy. Results LLNM was most commonly observed in area-Ⅲ(38.1%), and the two-segment metastasis pattern was the most prevalent(42.2%). There was no significant difference in the pattern of LLNM when the lesions were located in different areas of the gland(P>0.05). Multivariate Logistic regression analysis revealed that the location of the lesion, levels of free triiodothyronine(FT3), thyroid-stimulating hormone(TSH), thyroid peroxidase antibodies(TPOAB), and the number of central lymph node metastasis(CLNM)were independent risk factors for LLNM. The area under the curve of the nomogram prediction model is 0.851, indicating a high level of diagnostic accuracy for the established model. Conclusion The nomogram model, incorporating clinicopathological and ultrasonic characteristics, and laboratory results(the number of CLNMs, location of the lesion, FT3, TSH, TPOAB levels), proves to be effective in predicting LLNM in PTCs larger than 10 mm and holds promise for clinical application.

Key words: Papillary thyroid carcinoma, Lateral lymph node metastasis, Central lymph node metastasis, Thyroid stimulating hormone, Thyroid peroxidase antibody, Free triiodothyronine

CLC Number: 

  • R736.1
[1] 刘燕,曹广磊,陈丽.超声引导下细针穿刺和BRAFV600E分子检测在甲状腺癌诊断中的价值[J].山东大学学报(医学版), 2022, 60(10): 57-61. LIU Yan, CAO Guanglei, CHEN Li. Ultrasound-guided fine needle aspiration biopsy and BRAFV600E molecular detection in the diagnosis of thyroid cancer[J]. Journal of Shandong University(Health Sciences), 2022, 60(10): 57-61.
[2] Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.
[3] Heng Y, Feng S, Yang Z, et al. Features of lymph node metastasis and structural recurrence in papillary thyroid carcinoma located in the upper portion of the thyroid: a retrospective cohort study[J]. Front Endocrinol, 2022,12: 793997. doi:10.3389/fendo.2021.793997.
[4] Feng JW, Ye J, Hong LZ, et al. Nomograms for the prediction of lateral lymph node metastasis in papillary thyroid carcinoma: Stratification by size[J]. Front Oncol, 2022,12: 944414. doi:10.3389/fonc.2022.944414.
[5] Gao L, Li X, Xia Y, et al. Large-volume lateral lymph node metastasis predicts worse prognosis in papillary thyroid carcinoma patients with N1b[J]. Front Endocrinol,2022,12: 815207. doi:10.3389/fendo.2021.815207.
[6] 张宏,钱林学.甲状腺乳头状癌超声特征预测侧颈区淋巴结转移的研究[J].中国医药生物技术, 2023, 18(4): 344-349. ZHANG Hong, QIAN Linxue, Predictive value of ultrasonographic features of papillary thyroid carcinoma nodules for lateral cervical lymph node metastasis[J]. Chinese Medicinal Biotechnology, 2023, 18(4): 344-349.
[7] Song WJ, Um IC, Kwon SR, et al. Predictive factors of lymph node metastasis in papillary thyroid cancer[J]. PLoS One, 2023,18(11): e0294594. doi:10.1371/journal.pone.0294594.
[8] 邵长秀,贺青卿,庄晓璇,等.934例甲状腺微小乳头状癌颈淋巴结部位转移及危险因素[J].山东大学学报(医学版), 2023, 61(2): 57-64. SHAO Changxiu, HE Qingqing, ZHUANG Xiaoxuan. Patterns and risk factors of cervical lymph node metastasis in 934 cases of papillary thyroid microcarcinoma[J]. Journal of Shandong University(Health Sciences), 2023, 61(2): 57-64.
[9] Liu JJ, Liu LP, Zhang YJ, et al. Analysis of characteristics microvessel density of thyroid malignant and benign nodules on contrast-enhanced ultrasonography[J]. AUTD, 2018, 2(3): 167-172.
[10] 徐震纲,刘绍严.分化型甲状腺癌颈侧区淋巴结清扫专家共识(2017版)[J].中国实用外科杂志, 2017, 37(9): 985-991.
[11] Caliskan O, Unlu MT, Yanar C, et al. Predictive factors affecting the development of lateral lymph node metastasis in papillary thyroid cancer[J]. Sisli Etfal Hastan Tip Bul, 2023, 57(3): 312-319.
[12] White C, Weinstein MC, Fingeret AL, et al. Is less more? a microsimulation model comparing cost-effectiveness of the revised American Thyroid Associations 2015 to 2009 guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer[J]. Ann Surg, 2020, 271(4): 765-773.
[13] Takami H, Ito Y, Okamoto T, et al. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons[J]. World J Surg, 2011, 35(1): 111-121.
[14] Lai SW, Fan YL, Zhu YH, et al. Machine learning-based dynamic prediction of lateral lymph node metastasis in patients with papillary thyroid cancer[J]. Front Endocrinol, 2022, 13: 1019037. doi: 10.3389/fendo.2022.1019037.
[15] Arishi AA, Abualhana F, Sferra J. Horners syndrome following thyroid surgery[J]. Cureus, 2023,15(9): e45825. doi:10.7759/cureus.45825.
[16] Kim SK, Park I, Hur N, et al. Patterns, predictive factors and prognostic impact of multilevel metastasis in N1b papillary thyroid carcinoma[J]. Br J Surg, 2017, 104(7): 857-867.
[17] Feng Y, Min Y, Chen H, et al. Construction and validation of a nomogram for predicting cervical lymph node metastasis in classic papillary thyroid carcinoma[J]. J Endocrinol Invest, 2021, 44(10): 2203-2211.
[18] Feng JW, Hong LZ, Wang F, et al. A nomogram based on clinical and ultrasound characteristics to predict central lymph node metastasis of papillary thyroid carcinoma[J]. Front Endocrinol, 2021,12: 666315. doi:10.3389/fendo.2021.666315.
[19] So YK, Kim MJ, Kim S, et al. Lateral lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis for prevalence, risk factors, and location[J]. Int J Surg, 2018, 50: 94-103. doi: 10.1016/j.ijsu.2017.12.029.
[20] Liu XN, Duan YS, Yue K, et al. The optimal extent of lymph node dissection in N1b papillary thyroid microcarcinoma based on clinicopathological factors and preoperative ultrasonography[J]. Gland Surg, 2022,11(6): 1047-1056.
[21] Gong J, Zhu B, Liu W, et al. Risk factors for lymph node metastasis in papillary thyroid carcinoma: a retrospective study[J]. Horm Metab Res, 2023, 55(5): 315-322.
[22] Wang Y, Deng C, Shu X, et al. Risk factors and a prediction model of lateral lymph node metastasis in cN0 papillary thyroid carcinoma patients with 1-2 central lymph node metastases[J]. Front Endocrinol, 2021, 12: 716728. doi: 10.3389/fendo.2021.716728.
[23] Dolidze DD, Shabunin AV, Mumladze RB, et al. A narrative review of preventive central lymph node dissection in patients with papillary thyroid cancer- A necessity or an excess[J]. Front Oncol, 2022,12: 906695. doi:10.3389/fonc.2022.906695.
[24] Dou Y, Hu D, Chen Y, et al. PTC located in the upper pole is more prone to lateral lymph node metastasis and skip metastasis[J]. World J Surg Oncol, 2020, 18(1):188. doi:10.1186/s12957-020-01965-x.
[25] 何小景,刘洋,刘华朋,等.血清甲状腺激素及抗体水平与分化型甲状腺癌风险等级的关系[J].临床医学, 2024, 44(1): 36-38.
[26] Xu B, Gu SY, Zhou NM, et al. Association between thyroid stimulating hormone levels and papillary thyroid cancer risk: a meta-analysis[J]. Open Life Sci, 2023, 18(1): 20220671. doi: 10.1515/biol-2022-0671.
[27] Mao A, An N, Wang J, et al. Association between preoperative serum TSH and tumor status in patients with papillary thyroid microcarcinoma[J]. Endocrine, 2021, 73(3): 617-624.
[27] Xiang Y, Xu Y, Bhandari A, et al. Serum TSH levels are associated with postoperative recurrence and lymph node metastasis of papillary thyroid carcinoma[J]. Am J Transl Res, 2021,13(6): 6108-6116.
[29] Huang D, Zhi J, Zhang J, et al. Relationship between thyroid autoantibodies and recurrence of papillary thyroid carcinoma in children and adolescents[J]. Front Oncol, 2022, 12: 883591. doi: 10.3389/fonc.2022.883591.
[30] Yang Y, Liu J, Shi X, et al. Clinical and pathological characteristics of patients with papillary thyroid carcinoma coexisting with Hashimotos Thyroiditis: a retrospective cohort study[J]. Cancer Control, 2023, 30: 10732748231199647. doi:10.1177/10732748231199647.
[31] Huang K, Gao N, Bian D, et al. Associations of BRAFV600E, clinical pathology and imaging factors with the recurrence rate of papillary thyroid microcarcinoma[J]. Exp Ther Med, 2020, 20(6): 243. doi: 10.3892/etm.2020.9373.
[32] Chang Q, Zhang J, Wang Y, et al. Nomogram model based on preoperative serum thyroglobulin and clinical characteristics of papillary thyroid carcinoma to predict cervical lymph node metastasis[J]. Front Endocrinol, 2022,13: 937049. doi: 10.3389/fendo.2022.937049.
[33] Liu S, Liu C, Zhao L, et al. A prediction model incorporating the BRAFV600E protein status for determining the risk of cervical lateral lymph node metastasis in papillary thyroid cancer patients with central lymph node metastasis[J]. Eur J Surg Oncol, 2021, 47(11): 2774-2780.
[1] ZHANG Weiwei, HUA Fang, LIANG Chaoshuai, CHU Miaomiao, SUN Jiayi, FRANK Zaucke, XIN Wei. Thyroid stimulating hormone promotes chondrocyte differentiation via anti-inflammatory protein CTRP3 [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 1-8.
[2] WANG Yuyu, GAO Li, CHEN Shaohua. Association between cognitive impairment and thyroid function after acute ischemic stroke in 94 patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 56-61.
[3] SHI Fei, PAN Xiang, YANG Jianming. Analysis of life quality in 106 papillary thyroid carcinoma patients undergoing total thyroidectomy [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 87-92.
[4] ZHANG Lin, LI Jing, WANG Ze, ZHANG Jiangtao, MA Zengxiang, SHI Yuhua. Impact of thyroid-stimulating hormone on blood glucose and serum lipids in patients with polycystic ovary syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 80-84.
[5] SHEN Yan, ZUO Changting. Estimation of reference range for thyroid functional parameter in pregnant women of Jinan City, China [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(5): 34-38.
[6] ZHANG Wen-wen1, ZHANG Yan-ling1, WANG Jie1, GAO Ling2,YU Chun-xiao1, YAN Hui-li1, XU Jin1. Effects of thyroid stimulating hormone on osteoclast differentiation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(4): 6-10.
[7] LI Wan-hu, CUI Yong-chun, WANG Xiao-yue, LIANG Wen-juan. Application of ultrasonography to the diagnosis of Hashimoto′s thyroiditis with papillary thyroid carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(9): 140-143.
[8] LI Jian-zhou, LIU Xin, ZHANG Ling-yun, JIN Yong-jun. Relationship between preoperative serum TSH and  differentiated thyroid carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(1): 10-13.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!